Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models.

Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, Koup JR, Smith BJ, Koudriakova T.

Drug Metab Dispos. 2008 Jul;36(7):1267-74. doi: 10.1124/dmd.107.019711. Epub 2008 Apr 1.

PMID:
18381487
2.

A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node--ablated, His bundle-paced dog.

Nolan ER, Feng MR, Koup JR, Liu J, Turluck D, Zhang Y, Paulissen JB, Olivier NB, Miller T, Bailie MB.

J Pharmacol Toxicol Methods. 2006 Jan-Feb;53(1):1-10. Epub 2005 Apr 7.

PMID:
16399550
3.

How modeling and simulation have enhanced decision making in new drug development.

Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL.

J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):185-97. Epub 2005 Nov 7. Review.

PMID:
16283534
4.

A novel simultaneous modeling approach to estimate linearity of pharmacokinetic parameters, including saturation of intestinal efflux, in the rat.

Williams JA, Sahasrabudhe V, Walton J, Zhu T, Hudson G, Koup JR.

J Pharmacol Toxicol Methods. 2005 Nov-Dec;52(3):307-13. Epub 2005 Jun 23.

PMID:
15979348
5.

Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.

Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE.

Drug Metab Dispos. 2004 Nov;32(11):1201-8. Epub 2004 Aug 10. Review.

PMID:
15304429
6.

Drug interactions with clinafloxacin.

Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ.

Antimicrob Agents Chemother. 2001 Sep;45(9):2543-52.

7.

Clinafloxacin pharmacokinetics in subjects with various degrees of renal function.

Randinitis EJ, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ.

Antimicrob Agents Chemother. 2001 Sep;45(9):2536-42.

8.

Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis.

Olson SC, Bockbrader H, Boyd RA, Cook J, Koup JR, Lalonde RL, Siedlik PH, Powell JR.

Clin Pharmacokinet. 2000 May;38(5):449-59.

PMID:
10843462
9.

Clinical pharmacokinetics of troglitazone.

Loi CM, Young M, Randinitis E, Vassos A, Koup JR.

Clin Pharmacokinet. 1999 Aug;37(2):91-104. Review.

PMID:
10496299
10.

Steady-state pharmacokinetics and dose proportionality of troglitazone and its metabolites.

Loi CM, Alvey CW, Vassos AB, Randinitis EJ, Sedman AJ, Koup JR.

J Clin Pharmacol. 1999 Sep;39(9):920-6.

PMID:
10471982
11.

Effect of troglitazone on the pharmacokinetics of an oral contraceptive agent.

Loi CM, Stern R, Koup JR, Vassos AB, Knowlton P, Sedman AJ.

J Clin Pharmacol. 1999 Apr;39(4):410-7.

PMID:
10197300
12.

Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol.

Koup JR, Anderson GD, Loi CM.

J Clin Pharmacol. 1998 Sep;38(9):815-8.

PMID:
9753209
13.

Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.

Kugler AR, Annesley TM, Nordblom GD, Koup JR, Olson SC.

Clin Chem. 1998 Jul;44(7):1474-80.

14.

Effect of troglitazone on steady-state pharmacokinetics of digoxin.

Loi CM, Knowlton PW, Stern R, Randinitis EJ, Vassos AB, Koup JR, Sedman AJ.

J Clin Pharmacol. 1998 Feb;38(2):178-83.

PMID:
9549650
15.

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study.

Loi CM, Randinitis EJ, Vassos AB, Kazierad DJ, Koup JR, Sedman AJ.

J Clin Pharmacol. 1997 Dec;37(12):1114-20.

PMID:
9506006
16.

Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites.

Loi CM, Alvey CW, Randinitis EJ, Abel R, Young MA, Koup JR.

J Clin Pharmacol. 1997 Nov;37(11):1038-47.

PMID:
9505997
17.

Effect of age, gender, and race on steady state procainamide pharmacokinetics after administration of procanbid sustained-release tablets.

Koup JR, Abel RB, Smithers JA, Eldon MA, de Vries TM.

Ther Drug Monit. 1998 Feb;20(1):73-7.

PMID:
9485559
18.

Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady state phenytoin concentration.

Ludden TM, Allerheiligen SR, Browne TR, Koup JR.

Ther Drug Monit. 1991 Mar;13(2):120-5.

PMID:
2053118
19.

Theophylline dosage adjustment during enoxacin coadministration.

Koup JR, Toothaker RD, Posvar E, Sedman AJ, Colburn WA.

Antimicrob Agents Chemother. 1990 May;34(5):803-7.

20.

A single and multiple dose pharmacokinetic and metabolism study of meclofenamate sodium.

Koup JR, Tucker E, Thomas DJ, Kinkel AW, Sedman AJ, Dyer R, Sharoky M.

Biopharm Drug Dispos. 1990 Jan-Feb;11(1):1-15.

PMID:
2322633
21.

Dicloxacillin absorption and elimination in children.

Smith AL, Meeks CA, Koup JR, Opheim KE, Weber A, Vishwanathan CT.

Dev Pharmacol Ther. 1990;14(1):35-44.

PMID:
2311479
22.

The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.

Rogge MC, Solomon WR, Sedman AJ, Welling PG, Koup JR, Wagner JG.

Clin Pharmacol Ther. 1989 Oct;46(4):420-8.

23.

Disease states and drug pharmacokinetics.

Koup JR.

J Clin Pharmacol. 1989 Aug;29(8):674-9. Review. No abstract available.

PMID:
2674207
24.

Aging and drug interactions. II. Effect of phenytoin and smoking on the oxidation of theophylline and cortisol in healthy men.

Crowley JJ, Cusack BJ, Jue SG, Koup JR, Park BK, Vestal RE.

J Pharmacol Exp Ther. 1988 May;245(2):513-23.

PMID:
3367304
25.

Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.

Koup JR, Dubach UC, Brandt R, Wyss R, Stoeckel K.

Antimicrob Agents Chemother. 1988 Apr;32(4):573-9.

26.

Effect of oral activated charcoal on tobramycin clearance.

Davis RL, Koup JR, Roon RA, Opheim KE, Smith AN.

Antimicrob Agents Chemother. 1988 Feb;32(2):274-5.

27.

Plasma and synovial fluid meclofenamic acid concentrations in patients with rheumatoid arthritis of the knee.

Koup JR, Thomas D, Tucker E, Black A, Ruderman M, Dixon JA, Kinkel A.

Eur J Clin Pharmacol. 1988;35(2):199-202.

PMID:
3191939
28.

Cigarette smoking and theophylline metabolism: effects of phenytoin.

Crowley JJ, Cusack BJ, Jue SG, Koup JR, Vestal RE.

Clin Pharmacol Ther. 1987 Sep;42(3):334-40.

PMID:
3621789
29.

Pharmacokinetics of ciprofloxacin in cystic fibrosis.

Davis RL, Koup JR, Williams-Warren J, Weber A, Heggen L, Stempel D, Smith AL.

Antimicrob Agents Chemother. 1987 Jun;31(6):915-9.

30.

Effect of orally administered activated charcoal on vancomycin clearance.

Davis RL, Roon RA, Koup JR, Smith AL.

Antimicrob Agents Chemother. 1987 May;31(5):720-2.

31.

Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose.

Crowley JJ, Koup JR, Cusack BJ, Ludden TM, Vestal RE.

Eur J Clin Pharmacol. 1987;32(2):141-8.

PMID:
3582477
32.

Application of stable isotope methodology in the evaluation of sustained-release theophylline dosage forms.

Koup JR, Walker SB, Shapiro GG, Howald WN, Pierson WE, Bierman CW, Furukawa CT.

J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):752-4.

PMID:
3771962
33.

Predictive performance of computer dosing methods for tobramycin using two pharmacokinetic models and two weighting algorithms.

Murray KM, Bauer LA, Koup JR.

Clin Pharm. 1986 May;5(5):411-4. No abstract available.

PMID:
3720212
34.

The "red man's syndrome" and slow infusion of vancomycin.

Davis RL, Smith AL, Koup JR.

Ann Intern Med. 1986 Feb;104(2):285-6. No abstract available.

PMID:
3946972
35.

Pharmacokinetics of rifampin in children. II. Oral bioavailability.

Koup JR, Williams-Warren J, Viswanathan CT, Weber A, Smith AL.

Ther Drug Monit. 1986;8(1):17-22.

PMID:
3961891
36.

Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion.

Koup JR, Williams-Warren J, Weber A, Smith AL.

Ther Drug Monit. 1986;8(1):11-6.

PMID:
3961887
37.

Ceftriaxone pharmacokinetics during peritoneal dialysis.

Koup JR, Keller E, Neumann H, Stoeckel K.

Eur J Clin Pharmacol. 1986;30(3):303-7.

PMID:
3732365
38.

Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes.

Vestal RE, Thummel KE, Mercer GD, Koup JR.

Eur J Clin Pharmacol. 1986;30(1):113-20.

PMID:
3709624
39.

Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis.

Woolf RA, Koup JR, Smith AL, Hilman BC, Goldmann D, Williams-Warren J.

Clin Pharm. 1985 Nov-Dec;4(6):664-9.

PMID:
4075734
40.

Pharmacokinetics of three oral formulations of ciprofloxacin.

Davis RL, Koup JR, Williams-Warren J, Weber A, Smith AL.

Antimicrob Agents Chemother. 1985 Jul;28(1):74-7.

41.

Erythropoietin kinetics in normal and uremic sheep.

Mladenovic J, Eschbach JW, Koup JR, Garcia JF, Adamson JW.

J Lab Clin Med. 1985 Jun;105(6):659-63.

PMID:
3998618
42.

Clinical pharmacology of extended-spectrum penicillins in infants and children.

Wilson CB, Koup JR.

J Pediatr. 1985 Jun;106(6):1049-56. Review.

PMID:
3889255
44.

Pharmacokinetics of ceftriaxone in neonates and infants with meningitis.

Martin E, Koup JR, Paravicini U, Stoeckel K.

J Pediatr. 1984 Sep;105(3):475-81.

PMID:
6088747
45.

Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.

Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B.

J Pediatr. 1984 Jul;105(1):117-24.

PMID:
6376743
46.

Nonlinear regression program to individualize oral theophylline dosage.

Bauer LA, Black DJ, Koup JR.

Clin Pharm. 1984 May-Jun;3(3):288-90.

PMID:
6547379
47.

Multiple-dose nonlinear regression analysis program for the microcomputer.

Koup JR, Horn J.

Ther Drug Monit. 1984;6(1):51-7.

PMID:
6546816
48.

Multiple-dose non-linear regression analysis program. Aminoglycoside dose prediction.

Koup JR, Killen T, Bauer LA.

Clin Pharmacokinet. 1983 Sep-Oct;8(5):456-62.

PMID:
6627810
49.

Theophylline pharmacokinetics in an extremely obese patient.

Koup JR, Vawter TK.

Clin Pharm. 1983 Mar-Apr;2(2):181-3. No abstract available.

PMID:
6883948
50.

Single-point prediction methods: a critical review.

Koup JR.

Drug Intell Clin Pharm. 1982 Nov;16(11):855-62.

PMID:
7173047

Supplemental Content

Support Center